We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

By LabMedica International staff writers
Posted on 25 Apr 2024
Print article
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms that can be easily overlooked. Currently, the main method for sepsis testing involves complex blood culture tests that can take days to yield results. This approach, which has been standard for over 40 years, is only able to detect 'viable' organisms, thus missing a broader range of potential microbial analytes present in the blood. Now, a groundbreaking diagnostic system currently under development could revolutionize life-saving clinical decision-making for sepsis patients.

Deepull (Barcelona, Spain) has unveiled its UllCORE benchtop diagnostic system that is capable of delivering 50 reportable results within an hour. This system covers 95% of pathogens known to cause sepsis, including resistance genes. The real-time multiplex PCR system operates by extracting total microbial DNA from an 8 mL sample of whole blood, bypassing the traditional and time-consuming blood culture process. The UllCORE assay encompasses a broad array of bacterial targets, fungi, and genes that create antibiotic resistance, enhancing the ability of clinicians to make more informed decisions faster. This rapid and sensitive technology aims to reduce the risks associated with inappropriate antibiotic use, thereby aiding in the battle against antimicrobial resistance in hospital settings.

Preliminary results of the assay based on prospectively obtained specimens from patients with sepsis have shown high agreement with positive blood culture results. Remarkably, it has also been able to identify over twice the number of clinically relevant pathogens as compared to traditional blood cultures. While the focus is currently on sepsis, Deepull envisions broad applications for the UllCORE system in diagnosing a variety of acute infections. Deepull is actively seeking to build strong partnerships with hospitals and laboratories as it prepares to launch clinical trials in 2025.

“Introducing the UllCORE platform and its unique capabilities to the market is a significant milestone for deepull,” said Jordi Carrera, Chief Executive Officer and Co-Founder of deepull. “We are encouraged by early results based on prospectively obtained specimens from septic patients and look forward to initiating clinical trials next year, as well as refining the platform ahead of commercial launch. We believe our UllCORE system could transform the standard of care for sepsis diagnosis, for the benefit of patients globally.”

New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
C. difficile Positive Control
C. difficile Ag Positive Control for Rapid Test
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The lateral flow test could detect prostate cancer more quickly and with greater accuracy (Photo courtesy of Valley Diagnostics)

Groundbreaking Test Could Detect Prostate Cancer Within Minutes Via Urine Sample

In the UK, over 52,000 men are diagnosed with prostate cancer annually, with up to one-quarter of these cases identified at a later stage, requiring more intensive treatments. The cost to the NHS for these... Read more

Hematology

view channel
Image: The new test could improve specialist transplant and transfusion practice as well as blood banking (Photo courtesy of NHS Blood and Transplant)

New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape

The release of oxygen by red blood cells is a critical process for oxygenating the body's tissues, including organs and muscles, particularly in individuals receiving large blood transfusions.... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.